PramipexoleIn Restless Legs Syndrome

被引：0
作者：
Paul L. McCormack
M. Asif A. Siddiqui
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
CNS Drugs | 2007年 / 21卷
关键词：
Placebo Recipient; Pramipexole; Periodic Limb Movement; Periodic Limb Movement During Sleep; Coprimary Endpoint;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
▴ Pramipexole is an oral, non-ergoline dopamine agonist with selectivity for the dopamine D3 receptor, which was recently approved in the EU and the US for the treatment of idiopathic restless legs syndrome (RLS) in adults.
引用
收藏
页码：429 / 437
页数：8
相关论文
共 68 条
  • [1] Hening WA(2004)An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder Sleep 27 560-83
  • [2] Allen RP(2003)Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health Sleep Med 4 101-19
  • [3] Earley CJ(2007)Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome Am J Med 120 S13-21
  • [4] Allen RP(2006)EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep Eur J Neurol 13 1049-65
  • [5] Picchietti D(1998)Pramipexole: a review of its use in the management of early and advanced Parkinson’s disease Drugs Aging 12 495-514
  • [6] Hening WA(1998)Pharmacology of pramipexole, a dopamine D Clin Neuropharmacol 21 141-51
  • [7] Allen RP(1995)-preferring agonist useful in treating Parkinson’s disease Eur J Pharmacol 290 29-36
  • [8] Vignatelli L(1997)Pramipexole binding and activation of cloned and expressed dopamine D Mov Disord 12 66-5
  • [9] Billiard M(1996), D Clin Pharmacol Ther 59 183-17
  • [10] Clarenbach P(1996) and D Clin Pharmacol Ther 59 184-9
1234567